logo
ProjectGrant Award

Oncogenic signalling crosstalk between MYD88 and CD79B mutations

Grant award · Australia · Last reported Dec 2018

Source: GrantConnect

Lymphoma is a blood cancer of lymphocytes, which results from uncontrolled growth and survival. The advent of DNA sequencing revealed that many lymphomas carry concurrent mutations in two signalling molecules, MYD88 and CD79B. The project will investigate how these mutant proteins cooperatively dysregulate signalling to understand the pathogenesis of this disease. It will also reinforce the ration

Status
Prospective
Sector
Education, Hospital, Government
Location
Australia
Updated
19 Nov 2026
Source
GrantConnect

ConstructChat

Ask ConstructChat about Oncogenic signalling crosstalk between MYD88 and CD79B mutations

Pick a question to edit it, or write your own.

First answer free · no account

I am a

Project Information FAQ

Project Information

5 Q
The project “Oncogenic signalling crosstalk between MYD88 and CD79B mutations” is an infrastructure initiative in the Education sector, located in Australia. Taiyo aggregates data on it from GrantConnect.

Participants

Sponsoring Agency

Status

Original status

grant award

Taiyo status

Prospective

Taiyo last update

2026-11-19

Contact

Not available for this record.

Description

Description

Lymphoma is a blood cancer of lymphocytes, which results from uncontrolled growth and survival. The advent of DNA sequencing revealed that many lymphomas carry concurrent mutations in two signalling molecules, MYD88 and CD79B. The project will investigate how these mutant proteins cooperatively dysregulate signalling to understand the pathogenesis of this disease. It will also reinforce the rationale to use front-line drugs and identify new therapeutic targets.

Original sector

Medical Research

Budget

Location

Country

Australia

Source

Source

GrantConnect

URL

More Details

Record type

Project

Sector

Education, Hospital, Government

Article published date

2024-12-16

More on this project

Research

Free account

View all details

You are reading the public part. A free account opens the rest:

  • Every detail on this project
  • News and media coverage
  • Technical research
View all details

Free account · no card · lands you back on this project